NIH R01 · 2025
ATR Dependency as a Novel Therapeutic Target in Lethal RB Deficient ProstateCancer
Metastatic prostate cancer (mPCa) is incurable and responsible for most PCa associated mortality. Androgen deprivation therapy (ADT) is the primary line of treatment for mPCa. ADT initially extends survival but is not curative as the patient’s tumor acquires castration resistance (mCRPC). A majority of mCRPC remain dependent on the function of the androgen receptor (AR), though a subset of cases (approximately 20%), of resistance mechanisms are independent of AR activity (CRPC-AI). CRPC-AI adapt to ADT via lineage plasticity rather than a result of resistant mutations, adopting a phenotype no longer reliant on AR expression and signaling. These tumors may display neuroendocrine features, a…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.